Synopsis: Lupin Limited has strategically spun off two of its oncology drug candidates into newly formed U.S.-based Kaveri Therapeutics through its wholly owned subsidiary, Lupin Inc. In return for granting an exclusive perpetual license to the programs, Lupin has secured an 82.2 percent equity stake in Kaveri, allowing it to participate in the future value creation of the assets while accelerating their global clinical development.
Shares of Lupin Limited are likely to remain in focus after the company announced that its wholly owned subsidiary, Lupin Inc., USA, has entered into a licensing agreement with Kaveri Therapeutics Inc., under which it has granted an exclusive perpetual license for two of its oncology programs LNP7457 (PRMT5) and LNP8701 (SOS1). In exchange, Lupin has acquired an 82.2 percent equity stake in Kaveri, marking a strategic step to accelerate the development and commercialization of its innovative oncology pipeline.
Lupin Limited has a total market capitalization of approximately Rs.1,14,102 crore. The company’s shares were trading at Rs. 2490.50 apiece on the stock exchange, up by 0.48 percent. The stock has gained 6.48 percent over the last month. It touched a 52-week high of Rs. 2529.50 and a 52-week low of Rs. 1836.80.
According to the company’s exchange filing, Lupin Inc. has licensed the two oncology assets to Kaveri Therapeutics, a U.S.-based clinical-stage oncology company established in May 2026. In return, Lupin received 332,000 common shares, representing an 82.2 percent ownership in Kaveri. The licensed programs have been valued at USD 1.6 million, and Lupin will also provide seed funding to support the company’s initial operations and clinical development.
Kaveri Therapeutics will independently advance the two oncology candidates through global clinical trials while raising additional capital from external investors to fund future development. The company will focus on developing therapies for difficult-to-treat solid tumors, including lung, pancreatic, ovarian and central nervous system (CNS)-related cancers. Both drug candidates have already generated encouraging clinical data, having been presented at the American Society of Clinical Oncology (ASCO) meetings in 2025 and 2026, providing an early validation of their scientific potential.
The transaction reflects an increasingly popular strategy adopted by global pharmaceutical companies to unlock value from early-stage research assets. Instead of funding expensive late-stage clinical trials internally, companies create specialised biotechnology entities that can independently raise capital and focus entirely on drug development. This enables the parent company to reduce financial risk while retaining significant upside through equity ownership if the therapies achieve clinical and commercial success.
For Lupin, the structure offers several long-term strategic benefits. The company retains majority economic exposure through its 82.2 percent stake in Kaveri while allowing an experienced oncology-focused management team to accelerate clinical development. Successful progression of either oncology program could substantially enhance the value of Lupin’s investment in Kaveri, while also allowing the company to concentrate resources on its core branded, generic and specialty pharmaceutical businesses.
Commenting on the development, Vinita Gupta, Chief Executive Officer of Lupin, said the company is proud to have developed the oncology assets and believes that Kaveri’s experienced leadership team is well positioned to accelerate the development of targeted cancer therapies and bring meaningful innovation to patients worldwide.
The global oncology therapeutics market continues to be one of the fastest-growing segments within pharmaceuticals, driven by rising cancer incidence, advances in precision medicine and increasing investments in targeted therapies. Companies with differentiated oncology pipelines have attracted significant investor interest, with innovative cancer drugs often commanding premium valuations and strategic partnerships from large pharmaceutical companies.
For investors, the transaction represents a strategic value-unlocking initiative rather than a conventional asset sale. Lupin has retained substantial ownership in the newly created oncology company while transferring the high-cost clinical development process to a specialised platform. If Kaveri successfully advances these programs through clinical trials and secures regulatory approvals or strategic partnerships, Lupin could benefit through appreciation in the value of its equity stake while limiting development risks on its own balance sheet.
Incorporated in 1983, Lupin Limited is an innovation-led global pharmaceutical company headquartered in Mumbai. The company develops, manufactures and commercialises a diversified portfolio of branded and generic formulations, complex generics, biotechnology products and active pharmaceutical ingredients (APIs) across more than 100 countries, including the United States, India, South Africa, Asia Pacific (APAC), Latin America (LATAM), Europe and the Middle East. Lupin has established a strong presence in therapeutic areas such as respiratory, cardiovascular, diabetes, anti-infectives, gastrointestinal, central nervous system and women’s health, supported by 15 manufacturing facilities and seven research centres worldwide.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses arising from decisions based on this article. Please consult your investment advisor before investing.
